Adalta Ltd has released a press release.
Second US patent for AD-214
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from AdAlta
- BTB funding transferred to AD-214 inhalation program
- New pre-clinical data presented at Boston conference
- Corporate overview and IRD Invest 2021 presentation
- $4.0M Non-Dilutive Financing with Victorian Government
- Carina collaboration webinar presentation
Later from AdAlta
- AGM presentations & first iCAR-T data
- Inhaled AD-214 passes first development milestone
- Voluntary Suspension
- Reinstatement to Quotation
- Entitlement Offer Booklet
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta